is semaglutide bad for kidneys may lower the risk of kidney disease-related events by 24 - Semaglutidecreatinine slowed the progression of kidney disease by 24 Is Semaglutide Bad for Kidneys? Unpacking the Evidence

Semaglutidein CKD stage 4 The question of whether semaglutide is bad for kidneys is complex, with research presenting a nuanced pictureResearch shows that Ozempicmay lower the risk of kidney disease-related events by 24% in adults with CKD and Type 2 diabetes. Learn how Ozempic can benefit .... While some postmarketing reports suggest a potential for acute kidney injury (AKI), a significant body of evidence indicates that semaglutide, a GLP-1 receptor agonist widely known by brand names like Ozempic and Wegovy, can actually offer substantial kidney protection, particularly for individuals with type 2 diabetes and chronic kidney disease (CKD). The search keyword "is semaglutide bad for kidneys" prompts a deep dive into these findings to understand the true impact of this medication on renal health.

For individuals diagnosed with CKD, the effects of semaglutide are increasingly recognized as beneficial. Studies have demonstrated that semaglutide can significantly lower the risk of kidney failure or serious kidney problems by 24%. This protective effect extends to reducing the risk of kidney function decline and end-stage kidney disease. For instance, the FLOW study indicated that kidneys were better maintained with semaglutide, showing a slower yearly decline in eGFR levels. Furthermore, semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and CKD. It's important to note that while semaglutide is not currently FDA approved as a standalone treatment for kidney disease, its efficacy in managing related complications is leading to expansions in its approved indications, with some regulatory bodies, like the TGA, already approving it for reducing kidney function decline.

However, the concern regarding acute kidney injury (AKI) cannot be entirely dismissed. There have been a number of postmarketing reports of acute kidney injury (AKI) and worsening CKD in patients taking this GLP-1 receptor agonist.Long-term kidney outcomes of semaglutide in obesity and ... Some of these case reports describe semaglutide-induced acute kidney injury (AKI), particularly in individuals with pre-existing conditions like obesity and diabetes. It is crucial to acknowledge that while these reports exist, they often describe rare occurrences in specific patient populations. The overall consensus from extensive research, such as the SELECT trial, suggests a benefit of semaglutide on kidney outcomes, even in individuals with overweight/obesity without diabetes who have cardiovascular disease. These studies have indicated that semaglutide reduces kidney risks in these patient groups.

The mechanism by which semaglutide exerts its protective effects on the kidneys is multifaceted. As a GLP-1 RA, it influences glucose metabolism, blood pressure, and inflammation, all of which are critical factors in kidney health.作者：J Chaiban·2022·被引用次数：1—To our knowledge, only two cases 5 report acutekidneyinjury (AKI) that developed on a background of chronickidneydisease after startingsemaglutide. Research has shown that people taking semaglutide group also had a lower risk of dying from kidney disease or cardiovascular disease, highlighting its systemic benefits. The drug is used to lower the risk of worsening of kidney disease, and in some pivotal studies, semaglutide has been shown to slowed the progression of kidney disease by 24%.It is alsoused to lower the risk of worsening of kidney disease, kidney failure (end-stage kidney disease), and death caused by heart or blood vessel ...

It's worth addressing related queries such as whether semaglutide can cause kidney stones or kidney infection. Currently, there is no substantial scientific evidence directly linking semaglutide use to the formation of kidney stones or the development of kidney infections2025年3月31日—The US Food and Drug Administration (FDA) approved Ozempic® (active ingredientsemaglutide) as the only GLP-1 receptor agonist to reduce the risk of worsening .... The reported kidney-related side effects primarily revolve around AKI in a small subset of patients, and the vast majority of evidence points towards renoprotective benefits.

When considering semaglutide in CKD stage 4 or its impact on semaglutide creatinine levels, it's essential to consult with a healthcare professional.Semaglutide for weight loss (Ozempic) While the drug has shown promise in slowing the progression of CKD, individualized treatment plans are paramount.Semaglutide for weight loss (Ozempic) Some sources mention "Reduced kidney functioning" as a potential risk, but this is often in the context of broader health concerns associated with rapid weight loss or specific patient profiles.Semaglutide for weight loss (Ozempic) On the contrary, numerous studies reveal that semaglutide may lower the risk of kidney disease-related events by 24% in adults with CKD and Type 2 diabetesGLP-1 Receptor Agonists (GLP-1 RAs).

In conclusion, while a potential, albeit rare, risk of acute kidney injury (AKI) exists with semaglutide use, the prevailing scientific evidence strongly supports its role in protecting the kidneys. For individuals managing type 2 diabetes and CKD, the benefits of semaglutide, including a reduced risk of kidney failure and slowed disease progression, appear to significantly outweigh the potential risks. The research indicates that semaglutide significantly reduces the risk of major kidney disease events, making it a valuable therapeutic option under the guidance of a qualified healthcare provider. The ongoing exploration of semaglutide and its direct kidney protection continues to solidify its position as a potentially kidney-saving medication.Semaglutide Reduced Risk for Major Kidney Disease ...